Skeletal Events of Hormonal Treatment and Radiotherapy in Patient With Breast Cacer (NCT04792840) | Clinical Trial Compass
UnknownNot Applicable
Skeletal Events of Hormonal Treatment and Radiotherapy in Patient With Breast Cacer
100 participantsStarted 2021-12-01
Plain-language summary
study of lymphedema and skeletal events in breast cacer patient receiving adjuvant hormonal therapy and radiothearpy
Who can participate
Age range40 Years – 70 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Postmenopausal patients with positive diagnosis of stage 1-3 breast cancer and planned AI (anastrazole, letrozole) adjuvant treatment will be included in the study.
* Patients without known osteoporosis will included in the study, and before AI treatment began.
* Conventional RT course must be completed (50 Gy/25 fractions, 2 Gy/fraction, 5 days/week).
* Patients continue to receive adjuvant hormonal treatment (aromatase inhibitors) or adjuvant target therapy (trastuzumab) while monitoring late toxicities
Exclusion Criteria:
* Male patients
* Metastatic disease at presentation
* No definitive surgery
* Carcinoma in situ or other rare tumors of the breast as phyllodes tumors.